Get started
ADVERUM BIOTECHNOLOGIES INC USD0.0001AA

ADVERUM BIOTECHNOLOGIES INC USD0.0001

4.52USDD
−0.08−1.83%
At close at Mar 7, 19:21 GMT
USD
No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0HA3 trade ideas

Adverum Biotechnologies Inc. | Chart & Forecast SummaryKey Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Notes On Session # Adverum Biotechnologies Inc. - Double Formation * A+ Set Up)) At 16.5800 USD | Subdivision 1 * No Trade)) | Invalid Pattern Confirmation | Subdivision 2 - Triple Formation * (Continuation Argument)) At 10.3500 USD * Numbered Retracement | Downtrend Continuation | Subdivision 3 * Daily Time Frame | Trend Settings Condition Active Sessions On Relevant Range & Elemented Probabilities; European Session(Upwards) - US-Session(Downwards) - Asian Session(Ranging) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Neutral
CAPITALCOM:ADVM
by TradePolitics
ADVM - Biotech Long ShotBiotechs are still beaten up, especially the gene therapy disrupter stocks, so continuing to buy a little bit here and a little bit here of some of these stocks. These are lottery stocks, they have few if any marketable products, but the idea is if they do come out with a block buster, well winner winner chicken dinner!!! Adverum is into ocular gene therapy with several therapies in the pipeline with one to be late-stage clinical study. Reason for the buy? Well a nice insider buy trade of $2.5 million in July which can often be a sign that something is in the making, or at least they have a lot of faith in the company moving forward. Probably buy 100 shares here, that is a small under $700 position so if it goes to zero I am not hurting, but if it becomes a 10 or better bagger that is a nice hit. I mean various investors had the company above $200 for a while, so it is not unreasonable to get that type of move. However the chances of that are low which is why we keep our risk low. Anyways, good luck and I will touch base soon.
NLong
by goldbug1
Adverum Biotechnologies, Inc.On the above bi-Weekly chart price action has corrected over 90% since June 2020. A number of reasons now exist to be bullish , including: 1) A strong buy signal prints (not shown). 2) Regular bullish divergence . Multiple oscillators printing divergence. 3) Price action confirms support on past resistance. 4) Falling wedge breakout + backtest. Is it possible price action falls further? Sure. Is it probable? No. Ww Type: trade Risk: <=6% of portfolio Timeframe: Don’t know. Return: Don’t know Stop loss: <= 50 cents
NLong
by without_worries
7
ADVM Showing Strong Momentum Price recently broke out of 10 month triangle formation. I am looking at price support atop breakout level @16.25 and the accelerating divergence of the 50 MA and 200 MA without the two ever crossing. On Balance Volume appears to be primed for a move higher without pulling back to 100 EMA and the MACD appears to me to be primed for a reacceleration as well, which conveys continuation higher will come with high momentum and a large and fast move could be upon us. Holding the breakout level at 16.25 is critical to bull thesis, prior gap fill to $28.50 is certainly possible, $26 seems reasonable. I am looking to enter full position at 20.50, which was the close of the long upper wick candle May 6.
NLong
by ETrades1
ADVM Technical Analysis 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients.
NLong
by yura_trades
Adverum Biotechnologies Inc 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients. If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NLong
by yura_trades
ADVM Technical Analysis 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NLong
by yura_trades
ADVM Technical Analysis 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NLong
by yura_trades